complement hemolysis

With the deepening of research and the development of complement therapeutics, a variety of complement inhibitors, such as CD55, CD59, anti-C5 antibody, C1 inhibitor, have been approved and developed for human disease treatment. This requires a method to evaluate the inhibitory activity of these inhibitors, namely complement hemolysis inhibition assay. The inhibition activities can be determined by comparison of the hemolysis inhibition between normal complement samples with that of complement samples with inhibitors. Two references can be used as a measure of the activity of complement inhibition, one is the value of CH50 or AH50, the other is the hemolysis inhibition curve of complement samples with gradient dilution.